The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The global hereditary angioedema therapeutics market is set for substantial growth, with projections indicating a surge from $4.88 billion in 2022 to $5.74 billion in 2023 at a commendable CAGR of 17.7%. Looking ahead, the market is poised to reach an impressive $11.29 billion in 2027, reflecting a robust CAGR of 18.3%.

• Propelled by Prevalence: The primary driver behind this growth is the rising prevalence of hereditary angioedema (HAE), a rare genetic disorder marked by recurrent episodes of severe skin and mucous membrane swelling. These episodes, caused by excess fluid build-up, lead to emergency room visits and pose a significant healthcare challenge globally.
• Global Impact: According to Rare Disease Advisor, approximately 1 in every 50,000 individuals globally suffers from HAE, with prevalence estimates ranging from 1:10,000 to 1:150,000. In the US alone, HAE episodes contribute to 15,000 to 30,000 emergency room visits annually, underlining the urgency for effective therapeutics.

Leading the Charge: Key Players in the Field
Major players in the hereditary angioedema therapeutics market are at the forefront of developing innovative solutions and shaping the evolving landscape.

• Industry Leaders: Companies like Shire plc, Sanofi, and Pharming Healthcare Inc. play a pivotal role in addressing the challenges posed by HAE. Their commitment to research and development is crucial for advancing therapeutic options.
• Diverse Portfolio: The market is characterized by a diverse range of players, including Attune Pharmaceuticals, BioCryst Pharmaceuticals Inc., and GlaxoSmithKline plc., each contributing unique perspectives and therapeutic approaches.

The Innovation Wave: Product Advancements Take Center Stage
Product innovations are emerging as a key trend, with major companies introducing groundbreaking solutions to sustain their positions in the market.

• LICA Investigational Antisense Medicine: Notable innovations include ligand-conjugated (LICA) investigational antisense medicine and gene therapy. In March 2023, Intellia Therapeutics launched NTLA-2002, an Investigational New Drug (IND) approved by the United States Food and Drug Administration for HAE treatment. This in vivo genome editing candidate, after a single dose, permanently lowers plasma kallikrein protein activity, preventing HAE attacks.
• Strategic Phase 1/2 Trial: NTLA-2002’s ongoing Phase 1/2 trial now includes the US in the worldwide Phase 2 part, showcasing a strategic approach to global clinical research.

Segmenting for Precision: Understanding the Therapeutic Landscape
The hereditary angioedema therapeutics market is segmented to offer a nuanced understanding of therapeutic approaches.

1. By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2. By Route of Administration: Intravenous, Subcutaneous, Oral
3. By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4. By Application: Prophylaxis, On-demand

Regional Dynamics: North America Leads, Asia-Pacific Emerges
In 2022, North America asserted its dominance as the largest region in the global hereditary angioedema therapeutics market. However, the forecast signals a shift, with Asia-Pacific emerging as the fastest-growing region during the forecast period.

View More On The Hereditary Angioedema Therapeutics Market Report 2023 – https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

RequestA Sample Of The Global Hereditary Angioedema Therapeutics Market Report 2023:
https://www.thebusinessresearchcompany.com/sample_request?id=10810&type=smp

The Hereditary Angioedema Therapeutics Global Market Report 2023 provides a comprehensive overview on the hereditary angioedema therapeutics market size, trends and drivers, opportunities, strategies, and companies analysis. Through our reports businesses can effectively analyze data and frame well-informed strategies

View More Related Reports –
Cold Pain Therapy Global Market Report 2023
Hormone Therapy Global Market Report 2023
Testosterone Replacement Therapy Global Market Report 2023

Contact us at:
The Business Research Company:https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn:https://in.linkedin.com/company/the-business-research-company
YouTube:https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model:https://www.thebusinessresearchcompany.com/global-market-model